Bed Bath & Beyond (BBBY) Tops Q4 EPS by 17c

Bed Bath & Beyond (NASDAQ: BBBY) reported Q4 EPS of $0.38, $0.17 better than the analyst estimate of $0.21. Revenue for the quarter came in at $3.1 million versus the consensus estimate of $3.08 million.

• Comparable Sales Decrease 5.6%

Outlook

The Company's first quarter and full-year 2020 results will be unfavorably impacted by the COVID-19 pandemic. The duration and extent of the pandemic is highly uncertain, and Bed Bath & Beyond's results could be impacted in ways that are difficult to predict today. Due to the level of market uncertainty, the Company will not provide further financial guidance for fiscal 2020 at this time.

For earnings history and earnings-related data on Bed Bath & Beyond (BBBY) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c